An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
Novartis Pharmaceuticals
Summary
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Eligibility
- Age range
- 6–100 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Signed informed consent must be obtained for adult participants before any assessment is performed. Written informed assent and parental permission (age as per local law) must be obtained for pediatric participants before any assessment is performed. If participants reach age of consent (age as per local law) during the study, they will need to also sign the corresponding study informed consent(s). 2. Ability to communicate effectively with the investigator, to understand and willing to comply with the requirements of the study. 3. Participant has completed treatment pe…
Interventions
- BiologicalSecukinumab s.c. injection
Secukinumab pre-filled syringes (PFS) for s.c. injection
Locations (167)
- Providence Medical FoundationFullerton, California
- Purushotham Akther and Roshan Kotha MD IncLa Mesa, California
- Precn Comprehensive Clnl Rsch SolnsSan Leandro, California
- Orrin Troum MD and Medical AssociatesSanta Monica, California
- Inland Rheumatology Clinical Trials INCUpland, California
- Medvin Clinical ResearchVan Nuys, California